# Indigo Diabetes NV

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/indigo-diabetes

- Industry: Medical Devices & Equipment
- Headquarters: Gent, Belgium
- Website: www.indigomed.com
- Total disclosed funding: $28M
- Latest round: Series B (Jul 24, 2020)
- Investors on record: 13

## About

Indigo Diabetes NV specializes in chronic disease management, focusing on innovative monitoring solutions for metabolic health and offering advanced technology to enhance patient outcomes.Indigo Diabetes NV, founded in 2016 and headquartered in Gent, Belgium, develops monitoring systems for chronic diseases. The company has secured funding through 2 significant deals, with the most recent being a Series B round on July 27, 2020, raising EUR 38 million led by Fund+. The CEO and founder, Danaë Delbeke, has a history of entrepreneurship, although details about other ventures are not available.Indigo Diabetes NV is dedicated to revolutionizing chronic disease management through its flagship product, the Continuous Multi-Metabolite Monitoring (CMM®) system. This innovative device, implanted beneath the skin, continuously measures metabolites such as glucose, ketones, and lactate using advanced silicon photonics technology. The device provides real-time data to users via the Indigo app. The technology primarily targets individuals with chronic diseases, particularly diabetes, but also has applications in chronic kidney disease, oncology, cardiovascular health, and athletic performance, with initial focus on regions with high chronic disease prevalence.Indigo Diabetes NV generates revenue through direct-to-consumer sales and potential partnerships with healthcare providers. Their business model includes subscription services for ongoing support and software updates via the Indigo app, enhancing user engagement with their CMM® sensor. Revenue is expected to primarily come from individual users and healthcare professionals, reflecting a growing demand for advanced chronic disease management solutions, particularly in the context of real-time health monitoring.Indigo Diabetes NV plans to leverage its recent Series B funding of EUR 38 million, raised in July 2020, to expand its product offerings and market presence. The company is working on new product designs to enhance its monitoring systems and aims to enter additional international markets by the end of 2023, targeting regions with significant chronic disease challenges. This funding will support product development and strategic marketing efforts, facilitating the introduction of their innovative solutions to a broader audience.

## Funding rounds

- Series B, Jul 24, 2020, $20M — Capricorn Partners, Ackermans & van Haaren, PMV, Thuja Capital, Qbic Fund, Fund+, Sensinnovat, Parana Management Corp, Manuardeo, Imec.xpand, SOFI
- Series A, Dec 20, 2016, $7.5M — Capricorn Partners, PMV, Thuja Capital, Fidimec, Qbic Fund, Social Finance, Sensinnovat, Parana Management Corp, Manuardeo

## Investors

- Capricorn Partners (https://capitalatlas.ai/funds/capricorn-partners) — Series A, Series B
- PMV (https://capitalatlas.ai/funds/pmv) — Series A, Series B
- Thuja Capital (https://capitalatlas.ai/funds/thuja-capital) — Series A, Series B
- Fidimec — Series A
- Qbic Fund (https://capitalatlas.ai/funds/qbic-fund) — Series A, Series B
- Social Finance (https://capitalatlas.ai/funds/social-finance) — Series A
- Sensinnovat — Series A, Series B
- Parana Management Corp — Series A, Series B
- Manuardeo — Series A, Series B
- Ackermans & van Haaren (https://capitalatlas.ai/funds/ackermans-van-haaren) — Series B
- Fund+ (https://capitalatlas.ai/funds/fund) — Series B
- Imec.xpand (https://capitalatlas.ai/funds/imec-xpand) — Series B
- SOFI — Series B